Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Personalis Inc (NQ: PSNL )

3.220 -0.630 (-16.36%)
Streaming Delayed Price Updated: 10:05 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,291,974
Open 3.410
Bid (Size) 3.220 (3)
Ask (Size) 3.230 (1)
Prev. Close 3.850
Today's Range 3.130 - 3.450
52wk Range 0.8906 - 4.520
Shares Outstanding 48,518,901
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
Breaking Down Personalis: 4 Analysts Share Their Views
Via Benzinga

Performance

YTD
+57.85%
+57.85%
1 Month
+163.94%
+163.94%
3 Month
+155.56%
+155.56%
6 Month
+100.01%
+100.01%
1 Year
+49.08%
+49.08%

More News

Read More
Personalis to Participate at the TD Cowen 3rd Annual Tools / Dx Revolution Conference
From Personalis, Inc.
Via Business Wire
Personalis Provides Dial-in and Updated Date for ASCO Highlights Conference Call
From Personalis, Inc.
Via Business Wire
4 Analysts Have This To Say About Personalis
Via Benzinga
Personalis: Q4 Earnings Insights
Via Benzinga
ASCO Data Highlights NeXT Personal® Ultra-sensitive MRD Performance in Early-stage Breast Cancer Recurrence Detection and Immunotherapy Monitoring
From Personalis, Inc.
Via Business Wire
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Personalis Announces Start of Cancer MRD Testing Commercialization Collaboration with Tempus
From Personalis, Inc.
Via Business Wire
Personalis Announces Podium Presentations and Abstracts Accepted at ASCO 2024
From Personalis, Inc.
Via Business Wire
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
PSNL Stock Earnings: Personalis Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Personalis Reports First Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Personalis to Announce First Quarter 2024 Financial Results
From Personalis, Inc.
Via Business Wire
Cathie Wood's Ark Laps Up $3.3M Worth Of Tesla As Stock Falls For 3rd Straight Session, Sheds Shares Of This Sports Betting Company
Via Benzinga
Cathie Wood's Ark Invest Buys More Shares Of This Meta Platforms Competitor
Via Benzinga
Cathie Wood's Ark Continues Tesla Stock Buying Spree, Acquires Over $14M Worth Of Shares Amid Dip
Via Benzinga
Personalis to Present at the 23rd Annual Needham Virtual Healthcare Conference
From Personalis, Inc.
Via Business Wire
Data Showcasing NeXT Personal MRD Test to be Presented at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Personalis, Inc.
Via Business Wire
Personalis Announces Publication Validating NeXT Personal® Test for Ultra-sensitive MRD Detection and Cancer Treatment Response Monitoring
From Personalis, Inc.
Via Business Wire
Cathie Wood's Ark Invest Sells Another Tranche Of Block Shares, Even As Bitcoin Price Stages A Recovery
Via Benzinga
Cathie Wood's Ark Invest Isn't Done Selling Shares Of Jack Dorsey-Led Block Yet — Sheds $7.5M Worth of Stock As Bitcoin Price Drops
Via Benzinga
Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Personalis, Inc.
Via Business Wire
Cathie Wood Sells $13.15M Worth Of Coinbase Shares Amid Bitcoin Flirting With All-Time High Levels — Shops For Palantir Stock Instead
Via Benzinga
Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying
Via Benzinga
Topics Stocks
Exposures US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.